Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Trust for Professional Managers ActivePassive International Equity ETF (NY:APIE)

36.21 -0.16 (-0.44%)
Streaming Delayed Price Updated: 10:53 AM EDT, Oct 30, 2025 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Headline News about Trust for Professional Managers ActivePassive International Equity ETF

< Previous 1 2 Next >
Why Did BioNTech Stock Surge 10% Pre-Market Today?
Via Stocktwits
Sanofi’s New Experimental Eczema Drug Meets Goals Of Late-stage Trial, But Wall Street Expected More
Via Stocktwits
Novartis Fails To Block Heart Failure Drug’s Generic From Launching Through 2026: Report
Via Stocktwits
Novartis Gets Swiss Authority Nod For First Malaria Drug In Newborns, Young Infants
The company said that it now expects rapid approval for the treatment in eight African countries, including Burkina Faso, Côte d'Ivoire, Kenya, Malawi, Mozambique, Nigeria, Uganda, and Tanzania. 
Via Stocktwits
Topics Death Government
Novartis’ Blockbuster Drug Fails Late-Stage Trial In Disease Causing Blood Vessel Inflammation, But Retail Turns Bullish
Giant cell arteritis (GCA) is the most common form of systemic vasculitis, a group of rare autoimmune diseases characterized by inflammation of blood vessels. 
Via Stocktwits
US Judge Upholds FDA Decision To Remove Wegovy, Ozempic From Shortage List In Move Against Compounding Pharmacies
The judge said that the FDA had appropriately weighed supply and demand data for the drugs and properly removed them from the shortage list, Reuters reported. 
Via Stocktwits
Topics Lawsuit
Novo Nordisk’s Plan To Start Late-Stage Trial Of Investigational Obesity Drug Amycretin In 2026 Gets Retail Talking
The decision to advance the study of subcutaneous and oral Amycretin into the late stage is based on feedback received from regulators following mid-stage studies. 
Via Stocktwits
Mesoblast Gives Positive Update About Potential FDA Application For Heart Failure Therapy: Retail Sees ‘Inflection Point’
The company is also looking forward to a meeting with the FDA in early July to discuss a trial of Ryoncil in adults with steroid-refractory acute graft-versus-host disease. 
Via Stocktwits
Novo Nordisk’s $812M Deal With Deep Apple Lifts Retail Mood, Chatter Spikes To High Levels
Separately, chip-maker Nvidia also announced a collaboration with Novo Nordisk to accelerate drug discovery efforts through innovative AI use cases. 
Via Stocktwits
Topics Artificial Intelligence Economy
WeRide Partners With Renault To Provide Autonomous Shuttle At The French Open, But Retail’s Not Excited
The Robobus service covers 2.8 km in 12 minutes, connecting Avenue de la Porte d'Auteuil, Place de la Porte d'Auteuil, P1 Parking Carrefour des Anciens Combattants, and Village de Roland Garros. 
Via Stocktwits
Topics Artificial Intelligence
Roche Gets Positive Opinion For Approval Of Cancer Therapy In EU: Retail Yet To React
The company said that the European Commission is expected to make a decision soon regarding the approval for Itovebi. 
Via Stocktwits
Topics Government
Novo Nordisk To Sell Wegovy For $199 A Month As Compounding Ban Nears: Retail’s Bullish
The offer will be valid through June 30 and aims to encourage patients who previously used compounded versions of the drug to move to Wegovy. 
Via Stocktwits
WeRide Narrows Losses In Q1, Announces $100M Share Repurchase Program: Retail’s Thrilled
The China-based robotaxi company increased its total fleet size to over 1,200 units in the quarter. 
Via Stocktwits
Novo Nordisk CEO Lars Jørgensen Steps Down Amid Challenges, Retail Chatter Spikes
The company said it would announce the next CEO in “due course,” but did not provide a more definite timeline. 
Via Stocktwits
Tencent Revenue Tops Forecasts On Gaming Surge, AI Ad Gains As Stock Rallies
Gaming revenue grew 24% year-on-year, driven by the release of titles like ‘Dungeon & Fighter Mobile’ and ‘Delta Force.’ 
Via Stocktwits
Topics Artificial Intelligence Earnings
Novo Nordisk Stock Rises Pre-Market On Q1 Beat Despite Lowering Outlook – Retail’s Elated
Sales of Novo Nordisk’s flagship weight loss drug Wegovy surged 85% in the first quarter of the fiscal year 2025, while its diabetes treatment Ozempic posted an 18% increase. 
Via Stocktwits
Topics Earnings Law Enforcement
Novo Nordisk’s Weight-Loss Drug Wegovy Launched In Thailand, Marks Entry Into Southeast Asia
Enrico Canal Bruland, vice president and general manager of Novo's Thai subsidiary, told Reuters that the firm received approval from the Thai FDA in 2023. 
Via Stocktwits
Novo Nordisk Wins Another Legal Battle Against Compounding Of Wegovy, Ozempic: Retail’s Bullish
Steve Benz, legal and US general counsel of Novo Nordisk, said the company is “pleased” that the court rejected the compounders' attempts to “undermine” the FDA's decision that the shortages of Wegovy... 
Via Stocktwits
Topics Lawsuit
BYD Doubles Profit In Q1 2025 Driven By Strong Growth In Vehicle Sales: But Retail’s Unconvinced
The company reported a net profit attributable to shareholders of RMB 9.15 billion ($1.26 billion) on Friday, up from RMB 4.57 billion in the corresponding quarter of 2024, and aligning with its... 
Via Stocktwits
Saudi Aramco To Collaborate With Chinese EV Giant BYD To Achieve Breakthroughs In New Energy Vehicles
The agreement was signed by Saudi Aramco Technologies Company (SATC), a wholly owned subsidiary of Aramco, and aims to leverage the research and development teams of both companies. 
Via Stocktwits
Topics Economy Electric Vehicles Government
Novo Nordisk Warns Against Counterfeit Ozempic In US: Retail’s Unmoved
The company said the seized counterfeit products feature lot number PAR0362 and illegitimate serial numbers beginning with the first eight digits, 51746517. 
Via Stocktwits
Topics Economy
Novo Nordisk’s Controlling Shareholder Novo Holdings Reports Record Total Income, Investment Returns In 2024: Retail Stays Bullish
The company said that its earnings consist of income from dividends and the share repurchase programmes of Novo Group companies Novo Nordisk A/S and Novonesis A/S, as well as returns from its... 
Via Stocktwits
Novo Nordisk Signs $2B Deal For Obesity Drug With Chinese Biotech: Retail Sentiment Improves
Novo Nordisk will obtain exclusive worldwide rights to develop, manufacture, and commercialize the drug UBT251, while United Biotechnology will, however, retain the rights to the drug in mainland... 
Via Stocktwits
Sony Stock Surges After Q3 Earnings Beat, Raised Outlook: Retail’s Not Convinced
For full-year 2024, Sony expects revenue to be about JPY 13.2 trillion ($876 billion), 4% higher than its previous outlook. 
Via Stocktwits
Topics Earnings
Toyota Downgraded After Second Straight Profit Drop, But Stock Climbs As Annual Outlook Improves: Retail Stays Optimistic
Toyota also announced plans to establish a wholly owned company in Shanghai to develop and produce Lexus BEVs and batteries. 
Via Stocktwits
Adidas Stock In Focus On Reported Layoffs: Retail's On The Sidelines
Adidas shares have gained 5% over the past five days after the footwear and sports apparel maker reported strong preliminary Q4 earnings 
Via Stocktwits
Toyota To Delay EV Production In North America Due To Slowing Sales: Report
Toyota delays North American EV production to first half of 2026, citing slowing sales. Plans to launch 10 new EV models globally by 2026. 
Via Benzinga
Toyota Boosts Share Buyback Program: Details Here
Toyota increases share buyback plan to 1.2 trillion yen, reflecting stock price. With this increase, Toyota can now repurchase up to 315.5 billion yen (210 million shares). 
Via Benzinga
Alibaba Teams Up With Nvidia to Supercharge EVs for Chinese Automakers: Report
Alibaba's cloud unit partners with Nvidia to enhance autonomous driving for Chinese smart vehicles. U.S. sanctions on chipmakers impact AI efforts. 
Via Benzinga
Topics Artificial Intelligence
Jack Ma Urges Alibaba to Embrace Competition, Highlights Growth Opportunities
Jack Ma urges Alibaba to trust in market forces despite challenges and competition. Company reports 4% Y/Y growth and $3.34B net income in Q1 2024. 
Via Benzinga
< Previous 1 2 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.